Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2024-08-01 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos reports half-year 2024 financial results and provides second quarter business update.pdf
Earnings Release Classification · 100% confidence The document is an earnings release from Galapagos NV for the half-year 2024. It contains key financial highlights, business updates, and a summary table of financial performance. While it references a more detailed financial report available on their website, the document itself provides substantive financial data and analysis for the period, fitting the definition of an Earnings Release (ER). H1 2024
2024-08-01 English
Galapagos rapporteert halfjaarcijfers 2024 en geeft een update over de activiteiten in het tweede kwartaal.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Galapagos NV dated August 1, 2024, reporting its financial results for the first half of 2024. It contains substantive financial data, including a consolidated income statement table for the six months ending June 30, 2024, and detailed management commentary on business performance, R&D, and financial outlook. While it mentions that a full financial report is available on their website, the document itself provides the core financial results and analysis, qualifying it as an Interim/Quarterly Report (IR) rather than just a publication announcement. H1 2024
2024-08-01 Dutch
Half-year report 2024.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-year financial report 2024' and contains comprehensive financial statements, management reports, and an auditor's review for the six-month period ended 30 June 2024. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2024
2024-08-01 English
Halfjaarverslag 2024.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halfjaarverslag 2024' (Half-year report 2024) for Galapagos NV. It contains comprehensive financial statements, management reports, and an audit review for the six-month period ending June 30, 2024. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. H1 2024
2024-08-01 Dutch
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
Earnings Release Classification · 99% confidence The document is a press release dated June 14, 2024, announcing that Galapagos will present new data regarding its GLPG5101 candidate at the EHA 2024 congress. It details clinical trial results (safety, efficacy, response rates) from the ATALANTA-1 study and provides context on the drug and the company's platform. This format—a formal announcement of clinical/scientific data presentation, often including key results summaries and forward-looking statements—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses on announcing results that will be presented elsewhere (EHA 2024) and provides key financial/operational highlights rather than being a comprehensive quarterly/annual report (10-K or IR), 'ER' (Earnings Release) is the most appropriate classification for this type of material announcement, even though the content is scientific/clinical rather than purely financial earnings. It is not a transcript (CT), a formal regulatory filing (like 10-K), or a presentation itself (IP). Given the context of presenting 'new results' and summarizing them, ER fits best as the initial public disclosure of performance highlights. Q4 2023
2024-06-17 Dutch
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
Regulatory Filings Classification · 95% confidence The document is a press release announcing the presentation of new clinical data (safety and efficacy results from the Phase 1/2 ATALANTA-1 study for GLPG5101) at the European Hematology Association (EHA) 2024 Congress. It contains key financial/clinical highlights, quotes from management, and details about the study and the company. This format—an initial announcement of results or study updates, often preceding a full report or presentation—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses on presenting key results and updates rather than being a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification for this type of material, even though the content is clinical data rather than quarterly revenue figures. It is not a transcript (CT), a formal annual report (10-K), or a proxy statement (DEF 14A). It is a direct release of performance/study information.
2024-06-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.